116 related articles for article (PubMed ID: 36809990)
1. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
De Castro J; Insa A; Collado-Borrell R; Escudero-Vilaplana V; Martínez A; Fernandez E; Sullivan I; Arrabal N; Carcedo D; Manzaneque A
BMC Pulm Med; 2023 Feb; 23(1):69. PubMed ID: 36809990
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden of Recurrence in Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer: A Retrospective Study Using Nationwide Claims Data of South Korea.
Byun JY; Lee JE; Shim YB; Kim J; Lee SY; Shin BR; Yoon NR; Park MH; Lee EK
Adv Ther; 2023 Feb; 40(2):550-567. PubMed ID: 36404368
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs.
Apple J; DerSarkissian M; Shah A; Chang R; Chen Y; He X; Chun J
J Comp Eff Res; 2023 Nov; 12(11):e230107. PubMed ID: 37655686
[No Abstract] [Full Text] [Related]
4. Economic burden of breast cancer in northern Serbia.
Milovic M; Tamas T; Crnobrnja V; Paut Kusturica M
Front Public Health; 2023; 11():1265301. PubMed ID: 38162600
[TBL] [Abstract][Full Text] [Related]
5. Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico.
Arrieta O; Quintana-Carrillo RH; Ahumada-Curiel G; Corona-Cruz JF; Correa-Acevedo E; Zinser-Sierra J; de la Mata-Moya D; Mohar-Betancourt A; Morales-Oyarvide V; Reynales-Shigematsu LM
Tob Induc Dis; 2014; 12(1):25. PubMed ID: 25653577
[TBL] [Abstract][Full Text] [Related]
6. Economic assessment of NGS testing workflow for NSCLC in a healthcare setting.
Seminati D; L'Imperio V; Casati G; Ceku J; Pilla D; Scalia CR; Gragnano G; Pepe F; Pisapia P; Sala L; Cortinovis DL; Bono F; Malapelle U; Troncone G; Novello S; Pagni F
Heliyon; 2024 Apr; 10(7):e29272. PubMed ID: 38617925
[TBL] [Abstract][Full Text] [Related]
7. The evolution of non-small cell lung cancer metastases in TRACERx.
Al Bakir M; Huebner A; Martínez-Ruiz C; Grigoriadis K; Watkins TBK; Pich O; Moore DA; Veeriah S; Ward S; Laycock J; Johnson D; Rowan A; Razaq M; Akther M; Naceur-Lombardelli C; Prymas P; Toncheva A; Hessey S; Dietzen M; Colliver E; Frankell AM; Bunkum A; Lim EL; Karasaki T; Abbosh C; Hiley CT; Hill MS; Cook DE; Wilson GA; Salgado R; Nye E; Stone RK; Fennell DA; Price G; Kerr KM; Naidu B; Middleton G; Summers Y; Lindsay CR; Blackhall FH; Cave J; Blyth KG; Nair A; Ahmed A; Taylor MN; Procter AJ; Falzon M; Lawrence D; Navani N; Thakrar RM; Janes SM; Papadatos-Pastos D; Forster MD; Lee SM; Ahmad T; Quezada SA; Peggs KS; Van Loo P; Dive C; Hackshaw A; Birkbak NJ; Zaccaria S; ; Jamal-Hanjani M; McGranahan N; Swanton C
Nature; 2023 Apr; 616(7957):534-542. PubMed ID: 37046095
[TBL] [Abstract][Full Text] [Related]
8. Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine.
Graham DM; Leighl NB
Front Oncol; 2014; 4():258. PubMed ID: 25295228
[TBL] [Abstract][Full Text] [Related]
9. Direct and indirect economic burden of lung cancer in Denmark a nationwide study.
Gouliaev A; Risikesan J; Christensen NL; Rasmussen TR; Hilberg O; Ibsen R; Løkke A
Eur Clin Respir J; 2021; 8(1):1951963. PubMed ID: 34377377
[No Abstract] [Full Text] [Related]
10. First recurrence of small cell lung cancer presenting as subacute monoarticular arthritis.
McCormick JP; Trueick R; Connaughton J; McDonnell N
BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417237
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of early-stage non-small-cell lung cancer: the Value-Based Healthcare approach to address social disparities.
Marzorati C; Masiero M; Pravettoni G
Future Oncol; 2024 Apr; ():1-4. PubMed ID: 38660980
[No Abstract] [Full Text] [Related]
12. AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013.
Harbeck N; Scharl A; Thomssen C; Müller V
Breast Care (Basel); 2013 Jun; 8(3):181-5. PubMed ID: 24415967
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective.
Yip CY; Greystoke A; Abogunrin S; Belleli R; Di Maio D; Rouse P; Jovanoski N
Lung Cancer; 2023 May; 179():107171. PubMed ID: 36947997
[TBL] [Abstract][Full Text] [Related]
14. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.
Riano I; Abuali I; Sharma A; Durant J; Dragnev KH
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259381
[TBL] [Abstract][Full Text] [Related]
15. Survival and medical costs of non-small cell lung cancer patients according to the first-line treatment: An observational study using the Kyoto City Integrated Database.
Shimamoto T; Tateyama Y; Kobayashi D; Yamamoto K; Takahashi Y; Ueshima H; Sasaki K; Nakayama T; Iwami T
Thorac Cancer; 2023 Jun; 14(17):1574-1580. PubMed ID: 37082875
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.
Das M; Ogale S; Jovanoski N; Johnson A; Nguyen C; Bhagwakar J; Lee JS
Immunotherapy; 2023 Jun; 15(8):573-581. PubMed ID: 37021770
[TBL] [Abstract][Full Text] [Related]
17. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
Meunier A; Longworth L; Gomes M; Ramagopalan S; Garrison LP; Popat S
Pharmacoeconomics; 2023 Aug; 41(8):1011-1025. PubMed ID: 37296369
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
[TBL] [Abstract][Full Text] [Related]
19. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
[TBL] [Abstract][Full Text] [Related]
20. Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients.
Linardou H; Lampaki S; Koliou GA; Vozikis A; Boutis A; Nikolaidi A; Kontogiorgos I; Papakotoulas P; Christopoulou A; Spyratos D; Bafaloukos D; Psyrri A; Grivas A; Koumarianou A; Tsiakitzis K; Mauri D; Rigakos G; Aravantinos G; Papantoniou P; Oikonomopoulos G; Fountzilas E; Koufaki MI; Kaparelou M; Liolis E; Mountzios G; Kosmidis P; Fountzilas G; Samantas E
Anticancer Res; 2023 Jun; 43(6):2799-2812. PubMed ID: 37247889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
